Orange Biomed Co., Ltd – Trademark Portfolio
Entity Type: 03
Orange Biomed Co., Ltd holds 3 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 10 (Medical Apparatus) — 2 filings in this category. The portfolio also extends into Class 5 (Pharmaceuticals) across 4 Nice Classification classes. Currently, 3 trademarks are registered. Notable registered marks include ORANGEBIOMED and OBM RAPID A1C. The owner is based in Seoul.
301, 26 Muhakbong
28-gil, Seongdong-gu,
Seoul 04715 , KR
Showing of trademarks Trademarks
Trademark Classifications
Orange Biomed Co., Ltd's trademark portfolio spans 4 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes
Advertising; business management; business administration; office functions
Scientific and technological services; industrial analysis and research services
Frequently Asked Questions
How many trademarks does Orange Biomed Co., Ltd have?
Orange Biomed Co., Ltd has 3 U.S. trademarks filed with the USPTO. Of these, 3 registered.
What trademark classes does Orange Biomed Co., Ltd file in?
Orange Biomed Co., Ltd files trademarks across 4 Nice Classification classes. The most active classes are Class 10 (Medical Apparatus), Class 5 (Pharmaceuticals), Class 35 (Advertising & Business), Class 42 (Computer & Scientific). Class 10 covers surgical, medical, dental and veterinary apparatus and instruments.
What are Orange Biomed Co., Ltd's most well-known trademarks?
Orange Biomed Co., Ltd's registered trademark portfolio includes well-known marks such as ORANGEBIOMED and OBM RAPID A1C. These are among 3 currently registered trademarks in the portfolio.
What is Orange Biomed Co., Ltd's trademark registration success rate?
Orange Biomed Co., Ltd has a 100% trademark registration rate, with 3 out of 3 resolved applications resulting in successful registration. Currently, 0 applications are pending review.